Theravance Biopharma (TBPH) Upgraded by BidaskClub to “Sell”

Theravance Biopharma (NASDAQ:TBPH) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other research firms have also issued reports on TBPH. Robert W. Baird reiterated a “sell” rating and set a $22.00 target price on shares of Theravance Biopharma in a report on Wednesday, November 1st. Cantor Fitzgerald set a $55.00 target price on Theravance Biopharma and gave the stock a “buy” rating in a report on Wednesday, October 25th. Zacks Investment Research upgraded Theravance Biopharma from a “sell” rating to a “hold” rating and set a $37.00 target price on the stock in a report on Tuesday, October 10th. Needham & Company LLC reiterated a “buy” rating on shares of Theravance Biopharma in a report on Tuesday, December 5th. Finally, ValuEngine lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Three analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Theravance Biopharma has an average rating of “Hold” and an average target price of $41.86.

Shares of Theravance Biopharma (NASDAQ TBPH) opened at $28.32 on Friday. Theravance Biopharma has a twelve month low of $23.15 and a twelve month high of $43.44. The stock has a market capitalization of $1,515.44, a PE ratio of -5.48 and a beta of 2.10. The company has a current ratio of 7.53, a quick ratio of 7.21 and a debt-to-equity ratio of 1.21.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($0.05). Theravance Biopharma had a negative return on equity of 99.43% and a negative net margin of 1,604.87%. analysts expect that Theravance Biopharma will post -4.84 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. raised its stake in Theravance Biopharma by 4.2% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 199,677 shares of the biopharmaceutical company’s stock valued at $5,569,000 after buying an additional 8,119 shares during the period. Moneta Group Investment Advisors LLC bought a new stake in Theravance Biopharma in the third quarter valued at approximately $299,000. Wells Fargo & Company MN raised its stake in Theravance Biopharma by 32.0% in the third quarter. Wells Fargo & Company MN now owns 117,079 shares of the biopharmaceutical company’s stock valued at $4,009,000 after buying an additional 28,391 shares during the period. Legal & General Group Plc raised its stake in Theravance Biopharma by 15.7% in the third quarter. Legal & General Group Plc now owns 18,840 shares of the biopharmaceutical company’s stock valued at $646,000 after buying an additional 2,551 shares during the period. Finally, American International Group Inc. raised its stake in Theravance Biopharma by 8.1% in the third quarter. American International Group Inc. now owns 28,000 shares of the biopharmaceutical company’s stock valued at $959,000 after buying an additional 2,094 shares during the period. Hedge funds and other institutional investors own 86.34% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/20/theravance-biopharma-tbph-upgraded-by-bidaskclub-to-sell.html.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply